Peripheral T-cell Lymphoma

Aug 28, 2026

Summary Peripheral T-cell lymphoma (PTCL) is a rare and aggressive group of mature T-cell malignancies, representing approximately 10–15% of non-Hodgkin lymphomas in the US. CHOP remains the standard first-line treatment, but its intensive cytotoxic profile limits use in some patients.  ADCETRIS (brentuxi...

Aug 21, 2026

Summary T-cell malignancies, including Peripheral T-cell Lymphomas (PTCL) and cutaneous entities such as Cutaneous T-cell Lymphoma (CTCL), comprise a diverse and often aggressive group of cancers that are generally associated with poorer clinical outcomes compared with B-cell malignancies. The current CTCL t...

Jun 25, 2024

Alnylam's HELIOS-B Phase III Study of Vutrisiran Shows Positive Results, Meeting All Primary and Secondary Endpoints Alnylam Pharmaceuticals, Inc. reported encouraging topline outcomes from its HELIOS-B Phase III study of vutrisiran, an experimental RNAi therapy being developed to treat ATTR amyloidosis with car...

Sep 19, 2023

EBGLYSS Receives Positive CHMP Opinion for Moderate-to-Severe Atopic Dermatitis Almirall S.A. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the marketing authorization of EBGLYSS (lebrikizumab) for the treatment o...

Jan 14, 2022

The innovation in the oncology drug pipeline has resulted in a record number of FDA and EU approvals in recent years, as investigators and sponsors seek new and targeted treatments for individuals diagnosed with different types of cancers each year. In 2022, regulators will continue to evaluate new oncology therapi...